Research programme: respiratory syncytial virus therapeutics - Il-Yang PharmaceuticalsAlternative Names: RSV therapeutics - Il-Yang Pharmaceuticals
Latest Information Update: 08 Dec 2014
At a glance
- Originator Il-Yang
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 12 May 2014 Preclinical trials in Respiratory syncytial virus infections in South Korea (unspecified route)